The event will feature both company leadership and key investigators, who will discuss the CLOVER WaM study (NCT02952508) and full results. Details are as follows:
Conference Call Details
Date:
Time:
Dial-in number: 1-800-717-1738
Webcast link: click HERE
A replay of the conference call will be available on the Events section of the company’s investor relations website.
About Waldenstrom’s macroglobulinemia
Waldenstrom’s macroglobulinemia is a B-cell malignancy characterized by bone marrow infiltration of clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. The prevalence in the US is approximately 26,000 with 1,500-1,900 patients being diagnosed annually. Approximately 11,800 patients require treatment in the relapsed or refractory setting and there are an estimated 5,700 patients requiring third-line or greater therapy. There are no FDA approved treatment options for patients progressing on BTKi therapy. BTKi therapies do not demonstrate complete response rates and require continuous treatment. Approximately 50% of third-line patients not receiving treatment are likely to consider new treatment options. There is an established unmet need for new FDA approved treatments that provide a novel mechanism of action, increased deep durable responses, and time limited treatment, especially in heavily pretreated WM patients.
About
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chief Financial Officer
investors@cellectar.com
![](https://ml.globenewswire.com/media/YWVmNGI0ZTItMWU3Ny00OWNjLTgyZTMtMTJkMTI0MmFjYjZkLTUwMDA2MzkzNA==/tiny/Cellectar-Biosciences.png)
2024 GlobeNewswire, Inc., source